Tim Smith has joined Verseau Therapeutics as its chief business officer. Smith’s experience includes business development roles at Dova Pharmaceuticals, IDEAYA Biosciences (NASDAQ: [[ticker:IDYA]]), Cleave Biosciences, and Celgene (NASDAQ: [[ticker:CELG]]). Bedford, MA-based Verseau is developing a type of cancer immunotherapy called macrophage checkpoint modulators. Last month, the company closed $50 million in Series A financing.
Author: Frank Vinluan
Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.
Alkermes Eyes Brain Disorders and Beyond With $100M Deal for Rodin
[Updated 5:55 p.m. See below.] Rodin Therapeutics has limited data from human studies about its neurodegeneration drug, but the company’s new approach to treating brain disorders has proven attractive enough for Alkermes to plunk down $100 million to buy the startup. According to financial terms announced Monday, the cash sum is an upfront payment. Depending … Continue reading “Alkermes Eyes Brain Disorders and Beyond With $100M Deal for Rodin”
ResTORbio’s Respiratory Drug Flunks Phase 3 Test, Shattering Shares
A resTORbio respiratory drug has failed a late-stage test, and the company is stopping further development of the compound for lung infections in elderly patients. In the first of two Phase 3 studies, resTORbio on Friday released preliminary data showing that its drug, RTB101, did not beat a placebo. Though the Boston-based company won’t proceed … Continue reading “ResTORbio’s Respiratory Drug Flunks Phase 3 Test, Shattering Shares”
Bayer and Dewpoint Ink Deal for Drugs R&D at New Frontier of Biology
[Updated, 12:15 p.m. See below.] Inside of a cell, some proteins and RNA are concentrated in liquid droplets that assemble in formation during a variety of cellular functions. Dewpoint Therapeutics is making headway understanding the role these droplets play in disease, and that work now has Bayer as a research partner. Bayer and Dewpoint on … Continue reading “Bayer and Dewpoint Ink Deal for Drugs R&D at New Frontier of Biology”
Avidity Bio Adds $100M to Advance R&D of Muscle Disorder Drugs
Earlier this year, Avidity Biosciences and Eli Lilly began a partnership to develop new drugs based on the biotech’s technology for delivering genetic material to cells. On Wednesday, Lilly was among a group of investors that joined a $100 million financing for the company. The funding, a Series C round, was led by RTW Investments. … Continue reading “Avidity Bio Adds $100M to Advance R&D of Muscle Disorder Drugs”
NIBR’s Raman Departs for Chief Biz Dev Role at Flagship Pioneering
Prakash Raman has joined venture capital firm Flagship Pioneering in the newly created role of chief business development officer. Raman comes to Cambridge, MA-based Flagship from the Novartis Institutes for BioMedical Research (NIBR), where he was vice president and global head of business development and licensing. Flagship’s portfolio companies include epigenetics medicines developer Omega Therapeutics … Continue reading “NIBR’s Raman Departs for Chief Biz Dev Role at Flagship Pioneering”
FDA Again Halts Solid Bio’s Duchenne Gene Therapy Clinical Trial
The FDA has stopped a clinical trial testing a Solid Biosciences gene therapy for Duchenne muscular dystrophy after a patient developed complications associated with the experimental treatment. Cambridge, MA-based Solid Bio says the problems deemed to be related to the gene therapy included an immune system reaction, a decrease in red blood cells, kidney injury, … Continue reading “FDA Again Halts Solid Bio’s Duchenne Gene Therapy Clinical Trial”
TransEnterix CEO Pope Steps Down, Fernando Appointed Successor
Todd Pope, president and CEO of TransEnterix (NYSE American: [[ticker:TRXC]]) since 2008, has stepped down. The Research Triangle Park, NC-based surgical robotics company promoted Anthony Fernando to take Pope’s place. Fernando had been TransEnterix’s chief operating officer and chief technology officer. Pope will continue to advise the company to help with the transition of his … Continue reading “TransEnterix CEO Pope Steps Down, Fernando Appointed Successor”
Roche Challenger to Biogen’s SMA Drug Succeeds in Pivotal Study
A Roche drug in development as a treatment for spinal muscular atrophy achieved the main goals of a key study, helping to build the case that the drug could challenge a Biogen therapy already approved for the rare disorder. Roche announced Monday that its drug, risdiplam, met the main goal of showing improvement according to … Continue reading “Roche Challenger to Biogen’s SMA Drug Succeeds in Pivotal Study”
Neuroscience Is Taking the Spotlight at Xconomy’s Bay Area Xchange
These are heady times for neuroscience research. Startups developing new approaches to brain disorders are raising money to advance their discoveries toward clinical trials. One failed neuro drug is getting another shot. On Nov. 19 in San Francisco, we’ll hold the latest in our Xchange event series. What’s Next in Neuroscience Therapies will take a … Continue reading “Neuroscience Is Taking the Spotlight at Xconomy’s Bay Area Xchange”
Anemia Drug From Acceleron Pharma and Celgene Wins FDA Approval
[Updated 6:41 p.m. See below.] A drug that Celgene and Acceleron Pharma developed to treat low red blood cell levels in patients who have a rare blood disorder now has regulatory clearance to enter the market. The FDA on Friday approved luspatercept (Rebloyzl) for patients who have beta thalassemia, an inherited disorder that leads to … Continue reading “Anemia Drug From Acceleron Pharma and Celgene Wins FDA Approval”
Bio Roundup: Feds Sue Gilead, Biogen Eyes China, CRISPR’d Kidneys & More
During the state of the union address this year, President Trump pledged to end HIV transmission within the next decade. A key part of that plan is an HIV prevention drug made by Gilead Sciences. That drug has now become the center of a patent dispute between the Foster City, CA, drug maker and the … Continue reading “Bio Roundup: Feds Sue Gilead, Biogen Eyes China, CRISPR’d Kidneys & More”
Gilead’s Luisa Stamm Named Assembly Biosciences Chief Medical Officer
Luisa Stamm has joined Assembly Biosciences (NASDAQ: [[ticker:ASMB]]) as chief medical officer. Stamm comes to South San Francisco-based Assembly from Gilead Siences (NASDAQ: [[ticker:GILD]]), where she was executive director in the liver diseases therapeutic area, as well as executive director in the HIV and emerging viruses therapeutic area. Assembly is developing drugs for hepatitis B … Continue reading “Gilead’s Luisa Stamm Named Assembly Biosciences Chief Medical Officer”
Rubius Exec Dowden Departs for Entrada Chief Operating Officer Post
Entrada Therapeutics has appointed Nathan Dowden to serve as its chief operating officer. He joins Boston-based Entrada from Rubius Therapeutics, where he was senior vice president of strategy and corporate development. Entrada is developing drugs that that use cell-penetrating peptides to bring a therapy into a cell. Last year, the biotech raised $59 million in … Continue reading “Rubius Exec Dowden Departs for Entrada Chief Operating Officer Post”
eGenesis Lands $100M to Advance CRISPR-ed Pig Kidney to Human Test
Biotech startup eGenesis, which is applying gene editing to animal organs in order to make them suitable for human transplant, has raised $100 million to ramp up work on its kidney program and bring it into human testing. The Series B round of funding was led by the investment arm of Fresenius Medical Care, a … Continue reading “eGenesis Lands $100M to Advance CRISPR-ed Pig Kidney to Human Test”
Arkuda Unveils $44M and a Protein Restoration Approach to Dementia
The onset of one of the most devastating forms of dementia often comes with a misdiagnosis. Personality and behavioral changes in a patient can spark a hypothesis of depression or psychosis. Memory problems rouse suspicion of Alzheimer’s disease. By the time a physician determines frontotemporal dementia as the cause, the disease is well on its … Continue reading “Arkuda Unveils $44M and a Protein Restoration Approach to Dementia”
Biogen Adds Two More Biosimilars in $100M Deal with Samsung Bioepis
Biogen is bolstering its strategy of selling biosimilars—lower-cost versions of biological drugs that are losing patent protection—with a $100 million deal for rights to two eye products. The drug maker is also expanding its biosimilar scope to include China. Cambridge, MA-based Biogen (NASDAQ: [[ticker:BIIB]]) struck the deal with Samsung Bioepis, its joint venture with Samsung … Continue reading “Biogen Adds Two More Biosimilars in $100M Deal with Samsung Bioepis”
Stryker Adds to Trauma & Extremities Biz With $4B Wright Medical Deal
Medical device giant Stryker is strengthening its presence in trauma and extremities surgeries with a cash deal to acquire Wright Medical for $4 billion. According to deal terms announced Monday, Kalamazoo, MI-based Stryker (NYSE: [[ticker:SYK]]) will pay $30.75 per share, a nearly 40 percent premium compared to the Friday closing stock price of Wright Medical … Continue reading “Stryker Adds to Trauma & Extremities Biz With $4B Wright Medical Deal”
Gilead’s Sung Lee Joins Sangamo Therapeutics as CFO
Sangamo Therapeutics (NASDAQ: [[ticker:SGMO]]) has appointed Sung Lee to serve as executive vice president and chief financial officer. Lee joins Brisbane, CA-based Sangamo after 14 years at Gilead Sciences (NASDAQ: [[ticker:GILD]]), where he was most recently a senior vice president leading financial planning and analysis, and investor relations. Sangamo and partner Pfizer (NYSE: [[ticker:PFE]]) are … Continue reading “Gilead’s Sung Lee Joins Sangamo Therapeutics as CFO”
Checkmate Pharma Names Kleem Chaudhary Chief Business Officer
Kleem Chaudhary has been appointed chief business officer of Cambridge, MA-based Checkmate Pharmaceuticals. He was most recently head of business development & licensing at Biogen (NASDAQ: [[ticker:BIIB]]). Chaudhary’s experience also includes positions at Takeda Pharmaceutical (NYSE: [[ticker:TAK]]) and Novartis (NYSE: [[ticker:NVS]]). Checkmate’s lead drug CMP-001, a type of cancer drug called an oligonucleotide, is in … Continue reading “Checkmate Pharma Names Kleem Chaudhary Chief Business Officer”
Halozyme to Restructure After Pancreatic Cancer Drug Fails in Phase 3
An experimental Halozyme Therapeutics treatment for pancreatic cancer has failed a pivotal study, and the company is stopping further development of the drug and closing its oncology operations as part of a corporate restructuring. Halozyme (NASDAQ: [[ticker:HALO]]) announced Monday that its drug, PEGPH20, did not meet a Phase 3 study’s main goal of improving how … Continue reading “Halozyme to Restructure After Pancreatic Cancer Drug Fails in Phase 3”
Entasis’s Isaacs to Retire, Altarac Appointed Chief Medical Officer
David Altarac has been appointed chief medical officer of Entasis Therapeutics (NASDAQ: [[ticker:ETTX]]). He will succeed Robin Isaacs, who will retire from the Waltham, MA-based company at the end of the year. Entasis said Isaacs will continue to serve as an advisor. Altarac’s experience includes senior roles at Shire, NeoStem, and Merck (NYSE: [[ticker:MRK]]). Entasis, … Continue reading “Entasis’s Isaacs to Retire, Altarac Appointed Chief Medical Officer”
Aerie Names David Hollander Chief Research & Development Officer
David Hollander is joining Aerie Pharmaceuticals (NASDAQ: [[ticker:AERI]]) as chief research and development officer. Hollander most recently worked at Ora, where he was chief medical officer and senior vice president. His experience also includes more than a decade at Allergan (NYSE: [[ticker:AGN]]). Durham, NC-based Aerie has two FDA-approved glaucoma treatments: netarsudil (Rhopressa) and the netasudil … Continue reading “Aerie Names David Hollander Chief Research & Development Officer”
Biotech Roundup: Novartis on Hold, AMAG Vote, Neuro News & More
The brain has stymied many efforts to develop new neuroscience drugs, leading a number of big pharmaceutical companies to pull back on such R&D work. This week, Amgen joined them. Amgen (NASDAQ: [[ticker:AMGN]]) is ending its research and early development programs in neuroscience, the company announced during a conference call to discuss third-quarter financial results. … Continue reading “Biotech Roundup: Novartis on Hold, AMAG Vote, Neuro News & More”
Pinteon Gets $17M to Tackle Tau in Alzheimer’s, Other Brain Diseases
Beta amyloid grabs most of the headlines and research dollars for Alzheimer’s disease, but efforts to develop drugs targeting that brain protein have largely come up short. Pinteon Therapeutics is trying for a better outcome with drugs that block tau, a different protein that, despite also being associated with Alzheimer’s, has garnered much less attention. … Continue reading “Pinteon Gets $17M to Tackle Tau in Alzheimer’s, Other Brain Diseases”
Roche to Pay Dicerna Pharma $200M to Team Up on Hepatitis B Drug
Dicerna Pharmaceuticals’ research on medicines intended to stop a gene from producing a disease-causing protein has caught the eye of Roche, which is paying the company $200 million up front for global rights to its early-stage hepatitis B virus infection drug. According to deal terms announced Thursday, Dicerna (NASDAQ: [[ticker:DRNA]]) could earn up to $1.47 … Continue reading “Roche to Pay Dicerna Pharma $200M to Team Up on Hepatitis B Drug”
Gilead’s Matthew Sause to Join Roche Diagnostics as North America CEO
Roche Diagnostics has appointed Matthew Sause to serve as president and CEO of its North America operations. Sause is coming to Indianapolis-based Roche Diagnostics from Gilead Sciences (NASDAQ: [[ticker:GILD]]), where he is senior vice president and head of global commercial product. His experience includes 17 years at Roche, including time at the company’s diagnostics division. … Continue reading “Gilead’s Matthew Sause to Join Roche Diagnostics as North America CEO”
FDA Halts Novartis Gene Therapy Study Amid Animal Safety Concerns
Novartis must stop enrollment of a clinical trial testing its gene therapy for a rare, muscular disorder after safety concerns surfaced in data from an animal study. The FDA put a partial clinical hold on a Phase 1/2 study testing the therapy, Zolgensma, Novartis (NYSE: [[ticker:NVS]]) announced Wednesday. The decision doesn’t halt the study entirely; … Continue reading “FDA Halts Novartis Gene Therapy Study Amid Animal Safety Concerns”
Editas Medicine Appoints Judith Abrams Chief Medical Officer
Judith Abrams has joined Editas Medicine as (NASDAQ: [[ticker:EDIT]]) chief medical officer. She most recently worked at EMD Serono Research and Development Institute as the franchise lead in immunology and neurology, global drug safety innovation. Her experience includes positions at CorMedix, Celgene (NASDAQ: [[ticker:CELG]]), and Novo Nordisk (NYSE: [[ticker:NVO]]). Cambridge, MA-based Editas is developing gene-editing … Continue reading “Editas Medicine Appoints Judith Abrams Chief Medical Officer”
Acerta Pharma’s Ed Tucker Joins Mirum as Chief Medical Officer
Mirum Pharmaceuticals (NASDAQ: [[ticker:MIRM]]) has appointed Ed Tucker to serve as its chief medical officer. He was most recently the chief operating officer of AstraZeneca (NYSE: [[ticker:AZN]]) subsidiary Acerta Pharma. His experience also includes positions at Bayer, Janssen Pharmaceutica, and Genentech. Foster City, CA-based Mirum Pharma, which launched late last year, is developing drugs for … Continue reading “Acerta Pharma’s Ed Tucker Joins Mirum as Chief Medical Officer”
Assembly Bio Taps Gilead’s Thomas Russo as Chief Financial Officer
Thomas Russo has left Gilead Sciences (NASDAQ: [[ticker:GILD]]) to become chief financial officer of Assembly Biosciences (NASDAQ: [[ticker:ASMB]]). Russo held a number of positions during his seven years at Gilead, and was most recently vice president and head of commercial finance. His experience also includes posts at Robert W. Baird & Co. and Merck (NYSE: … Continue reading “Assembly Bio Taps Gilead’s Thomas Russo as Chief Financial Officer”
With Ex-Medivation Exec Hung at Helm, Nuvation Nabs $275M for Cancer
Nuvation Bio peeked out from stealth mode Monday to reveal $275 million in financing and an executive team stacked with biotech veterans. The cancer drug developer, which has offices in New York and San Francisco, is led by founder, president, and CEO David Hung, the former chief executive who steered Medivation to a $14.3 billion … Continue reading “With Ex-Medivation Exec Hung at Helm, Nuvation Nabs $275M for Cancer”
Atara Bio’s Chief Scientific Officer Haqq Departs for Another Company
Atara Biotherapeutics (NASDAQ: [[ticker:ATRA]]) is losing two executives to private companies. Christopher Haqq, Atara’s first employee and its chief scientific officer since 2012, is leaving to join a firm that “aligns with his other scientific interests and the current needs of his family,” the South San Francisco-based company announced late Friday. Haqq will continue to … Continue reading “Atara Bio’s Chief Scientific Officer Haqq Departs for Another Company”
Ex-Nightstar Exec Ozden Joins Akouos as Chief Development Officer
Rabia Ozden has joined Akouos as chief development officer. She was most recently the chief medical officer of gene therapy developer Nightstar Therapeutics, which was acquired by Biogen (NASDAQ: [[ticker:BIIB]]) earlier this year for $800 million. Boston-based Akouos is developing gene therapies to address inherited forms of hearing loss.
Former Quartet, Knewton Exec David Liu Joins Sonde Health as CEO
Sonde Health, a company developing technology to monitor and diagnose people by analyzing their speech, has appointed David Liu to serve as CEO. Liu is the former president and chief operating officer at Quartet, a company applying technology to mental healthcare. His experience also includes serving as president and chief operating officer of education technology … Continue reading “Former Quartet, Knewton Exec David Liu Joins Sonde Health as CEO”
Akcea Therapeutics Promotes Kyle Jenne to Chief Commercial Officer
Akcea Therapeutics (NASDAQ: [[ticker:AKCA]]) has promoted Kyle Jenne to chief commercial officer. Jenne joined Boston-based Akea in 2017 as US commercial head. His appointment comes month after a corporate shakeup that led to the departure of three executives. Akcea is working to commercialize inotersen (Tegsedi), a drug approved by the FDA last year as a … Continue reading “Akcea Therapeutics Promotes Kyle Jenne to Chief Commercial Officer”
Rheos Medicines Taps Barbara Fox as Chief Executive
Barbara Fox is the new CEO of Rheos Medicines. She was most recently chief executive of Tilos Therapeutics, which was acquired by Merck (NYSE: [[ticker:MRK]]) earlier this year. Fox succeeds interim Rheos CEO Abbie Celniker, a partner at Third Rock Ventures. Celniker will remain chair of the Rheos board of directors. Cambridge, MA-based Rheos emerged … Continue reading “Rheos Medicines Taps Barbara Fox as Chief Executive”
Acorda Cuts Staff 25% and Restructures to Keep Focus on Parkinson’s Drug
Acorda Therapeutics is laying off about one quarter of its staff in order to save money and focus its remaining resources on commercializing a Parkinson’s disease drug that launched earlier this year. Ardsley, NY-based Acorda (NASDAQ: [[ticker:ACOR]]) said late Wednesday that it expects the workforce cuts will save $21 million annually. Most of the cuts … Continue reading “Acorda Cuts Staff 25% and Restructures to Keep Focus on Parkinson’s Drug”
Backed by $50M, Verseau Launches to Reprogram Immune Cells Against Cancer
Cancer therapies that harness the immune system don’t work for all patients. Verseau Therapeutics aims to bring cancer immunotherapy to more people by targeting a type of immune cell present in the vast majority of tumors and directing it to fight the disease. Verseau launched Monday backed by $50 million in financing. The Bedford, MA-based … Continue reading “Backed by $50M, Verseau Launches to Reprogram Immune Cells Against Cancer”
Bio Roundup: Ichnos Emerges, Beyond CAR-T, BridgeBio Bails & More
New brand-name drugs typically grab the life science headlines. A venture capital firm will invest tens of millions to develop one and a pharmaceutical company hopes to recoup hundreds of millions by selling it. But a shortage of one particular chemotherapy is showing the crucial role generic drugs play in healthcare. This week, The New … Continue reading “Bio Roundup: Ichnos Emerges, Beyond CAR-T, BridgeBio Bails & More”
CytomX Taps BeiGene’s Amy Peterson for Chief Development Officer
Amy Peterson has joined CytomX Therapeutics (NASDAQ: [[ticker:CTMX]]) as executive vice president and chief development officer. Peterson was most recently chief medical officer of immune-oncology at BeiGene (NASDAQ: [[ticker:BGNE]]). Her experience also includes positions at Medivation and Roche subsidiary Genentech. South San Francisco-based CytomX is developing antibody drugs that treat cancer.
ArsenalBio Launches With $85M for “Programmable” T Cell Therapies
Cell therapies are made by tinkering with a patient’s immune cells so that they can better recognize and destroy cancer cells. These drugs give patients another treatment option for certain cancers that haven’t responded to anything else. ArsenalBio CEO Ken Drazan aims to take cell therapy even further. Arsenal is developing technology that adds capabilities … Continue reading “ArsenalBio Launches With $85M for “Programmable” T Cell Therapies”
Eli Lilly Drug Acquired in Armo Deal Fails Pancreatic Cancer Test
An experimental drug that was the centerpiece of a $1.6 billion Eli Lilly acquisition last year has now failed a pivotal test in pancreatic cancer. Eli Lilly (NYSE: [[ticker:LLY]]) said Wednesday that patients treated with its drug candidate pegilodecakin, plus chemotherapy, did not live longer than patients treated with chemotherapy alone, falling short of the … Continue reading “Eli Lilly Drug Acquired in Armo Deal Fails Pancreatic Cancer Test”
Alexion to Buy Achillion in $930M Marriage of Rare Disease Drug Firms
Alexion Pharmaceuticals is acquiring Achillion Pharmaceuticals for $930 million, a deal that could strengthen its position providing treatments for a rare blood disorder. According to financial terms announced Wednesday, Boston-based Alexion (NASDAQ: [[ticker:ALXN]]) will pay $6.30 per share of Achillion (NASDAQ: [[ticker:ACHN]]) stock, which is an 80 percent premium to Achillion’s closing stock price on … Continue reading “Alexion to Buy Achillion in $930M Marriage of Rare Disease Drug Firms”
Checkmate Pharmaceuticals Names Wooldridge Chief Medical Officer
James Wooldridge has joined Checkmate Pharmaceuticals as chief medical officer, the same position he held most recently at Aeglea BioTherapeutics. Wooldridge’s experience also includes more than a decade at Eli Lilly (NYSE: [[ticker:LLY]]), where he held several positions in cancer drug development. Cambridge, MA-based Checkmate is developing a type of cancer drug called an oligonucleotide. The … Continue reading “Checkmate Pharmaceuticals Names Wooldridge Chief Medical Officer”
Second Genome’s McClure Joins Aligos as Chief Medical Officer
Matthew McClure has been appointed executive vice president and chief medical officer of South San Francisco-based Aligos Therapeutics. He was most recently the chief medical officer of Second Genome. McClure’s experience also includes time at InterMune, which was acquired by Roche in 2014. Preclinical-stage Aligos is developing treatments for liver diseases and viral infections.
Cyteir Adds $40M for Clinical Test of “Synthetically Lethal” Cancer Drug
Cyteir Therapeutics has $40.2 million more in cash to support early-stage tests of a drug intended to treat cancer by targeting a tumor repair mechanism. The new cash that Cyteir announced Tuesday adds to a Series B round of funding it raised last year. The Lexington, MA-based company says the amount invested in the round … Continue reading “Cyteir Adds $40M for Clinical Test of “Synthetically Lethal” Cancer Drug”
Revance CEO Browne Resigns, Board Member Foley Appointed Successor
Dan Browne has stepped down as president and CEO of Revance Therapeutics (NASDAQ: [[ticker:RVNC]]) due to what the company describes as “a misjudgement in handling an employee matter.” The Newark, CA-based drug developer gave no other details. Browne has also resigned from Revance’s board of directors. In a securities filing, Revance said Browne’s departure was … Continue reading “Revance CEO Browne Resigns, Board Member Foley Appointed Successor”
Parexel’s Washburn Named Lyra Therapeutics Chief Medical Officer
Dana Washburn has been appointed chief medical officer of Lyra Therapeutics. Washburn comes to Watertown, MA-based Lyra from Parexel, where he was corporate vice president and head of global medical services. Lyra develops treatments for ear, nose, and throat diseases. Last year, the company closed $29.5 million in Series B financing to support mid-stage tests … Continue reading “Parexel’s Washburn Named Lyra Therapeutics Chief Medical Officer”
FDA OKs Lilly’s Lasmiditan, First New Acute Migraine Drug in Decades
Eli Lilly won FDA approval for a migraine drug on Friday, giving the pharmaceutical giant a second medication that addresses the condition that causes millions of people to experience severe headaches and other debilitating symptoms. The FDA approved the drug, lasmiditan (Reyvow), as a treatment for acute migraine; it’s meant to be taken after the … Continue reading “FDA OKs Lilly’s Lasmiditan, First New Acute Migraine Drug in Decades”